Greenleaf Trust Sells 445 Shares of Novo Nordisk A/S (NYSE:NVO)

Greenleaf Trust lowered its position in Novo Nordisk A/S (NYSE:NVO) by 0.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,909 shares of the company’s stock after selling 445 shares during the period. Greenleaf Trust’s holdings in Novo Nordisk A/S were worth $6,818,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of NVO. Institute for Wealth Management LLC. lifted its holdings in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. Institute for Wealth Management LLC. now owns 12,668 shares of the company’s stock valued at $1,311,000 after purchasing an additional 474 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in Novo Nordisk A/S by 99.8% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 2,142 shares of the company’s stock valued at $222,000 after buying an additional 1,070 shares in the last quarter. Cambridge Trust Co. raised its stake in Novo Nordisk A/S by 0.5% in the fourth quarter. Cambridge Trust Co. now owns 100,857 shares of the company’s stock valued at $10,434,000 after buying an additional 525 shares during the last quarter. Oliver Lagore Vanvalin Investment Group boosted its holdings in Novo Nordisk A/S by 69.2% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 12,091 shares of the company’s stock worth $1,251,000 after acquiring an additional 4,945 shares in the last quarter. Finally, Twin Capital Management Inc. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $213,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. Finally, UBS Group assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $0.05 during mid-day trading on Friday, hitting $122.70. The company had a trading volume of 5,181,119 shares, compared to its average volume of 4,882,816. The company has a market capitalization of $550.62 billion, a price-to-earnings ratio of 45.55, a P/E/G ratio of 2.08 and a beta of 0.41. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The company’s fifty day moving average is $126.36 and its 200-day moving average is $110.50. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Equities research analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a $0.664 dividend. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.